Although ADI1 (acireductone dioxygenase 1) as an enzyme in the methionine de novo and salvage pathway has been considered as a tumor suppressor in prostate cancer or hepatocellular carcinoma [30], our study found that higher ADI1 gene expression was associated with poor overall survival of glioma patients. This evidence concerns the gene ADI1 and prostate cancer.